Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Current Trends and Movements in Managing Pulmonary Arterial Hypertension in Korea

  • Jaeho Seung (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea, College of Medicine, Cardiovascular Center, Seoul St. Mary's Hospital) ;
  • Hun-Jun Park (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea, College of Medicine, Cardiovascular Center, Seoul St. Mary's Hospital)
  • Received : 2023.03.01
  • Accepted : 2023.03.05
  • Published : 2023.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

Acknowledgement

The authors received no financial support for the research, authorship, and/or publication of this article.

References

  1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53:1801913. 
  2. Maron BA, Hess E, Maddox TM, et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program. Circulation 2016;133:1240-8.  https://doi.org/10.1161/CIRCULATIONAHA.115.020207
  3. Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA 2022;327:1379-91.  https://doi.org/10.1001/jama.2022.4402
  4. Galie N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015;373:834-44.  https://doi.org/10.1056/NEJMoa1413687
  5. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.  https://doi.org/10.7326/0003-4819-115-5-343
  6. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest 2012;142:448-56.  https://doi.org/10.1378/chest.11-1460
  7. Jang AY, Lee H, Kim HC, Chung JW. Epidemiology of PAH in Korea: an analysis of the national health insurance data, 2002-2018. Korean Circ J 2023;53:313-27. https://doi.org/10.4070/kcj.2022.0231
  8. Lim SS, Lee W, Kim YK, et al. The cumulative incidence and trends of rare diseases in South Korea: a nationwide study of the administrative data from the National Health Insurance Service database from 2011-2015. Orphanet J Rare Dis 2019;14:49. 
  9. Lee JH, Hwang KK. End-of-life care for end-stage heart failure patients. Korean Circ J 2022;52:659-79.  https://doi.org/10.4070/kcj.2022.0211
  10. Oh S, Jung JH, Ahn KJ, et al. Stem cell and exosome therapy in pulmonary hypertension. Korean Circ J 2022;52:110-22. https://doi.org/10.4070/kcj.2021.0191